Damon Thomas
Family Medicine · Crane, MONPI 1023100773
Payments from drug & device makers
Across 332 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$971
- Lilly USA, LLC$918
- Novo Nordisk$632
- GSK$477
- Abbott$378
- Boehringer Ingelheim$352
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,346100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $971 |
| Lilly USA, LLC | 58 | $918 |
| Novo Nordisk | 39 | $632 |
| GSK | 37 | $477 |
| Abbott | 20 | $378 |
| Boehringer Ingelheim | 24 | $352 |
| Otsuka America Pharmaceutical, Inc. | 13 | $208 |
| Pfizer | 10 | $177 |
| Xeris Pharmaceuticals, Inc. | 8 | $128 |
| Merck | 7 | $109 |
| Mylan Specialty L.p. | 7 | $108 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $106 |
| Astellas Pharma US Inc | 4 | $97 |
| Dexcom, Inc. | 4 | $92 |
| Sanofi-aventis U.S. LLC | 6 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $75 |
| Biogen | 3 | $63 |
| Idorsia Pharmaceuticals US Inc | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Lundbeck LLC | 3 | $46 |
| Johnson & Johnson | 3 | $46 |
| Amgen | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| AbbVie | 1 | $26 |
| Alkermes, Inc. | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Novartis | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Bayer | 1 | $16 |
| Eisai Inc. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
How this compares
$5,360 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 127 | $94,290 |
| OzempicSemaglutide | 76 | $77,047 |
| TrulicityDulaglutide | 76 | $76,404 |
| MounjaroTirzepatide | 68 | $71,579 |
| JanuviaSitagliptin Phosphate | 88 | $64,444 |
| OtezlaApremilast | 11 | $53,138 |
| EliquisApixaban | 71 | $48,519 |
| JardianceEmpagliflozin | 39 | $30,889 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 56 | $30,607 |
| FarxigaDapagliflozin Propanediol | 40 | $29,516 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $28,356 |
| XareltoRivaroxaban | 47 | $27,954 |
| OxycontinOxycodone Hcl | 24 | $26,760 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $25,991 |
| Spiriva RespimatTiotropium Bromide | 40 | $21,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $918 | $147,983144 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $477 | $127,431182 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat, Tradjenta | $352 | $98,561165 claims |
| Novo NordiskOzempic | $632 | $77,04776 claims |
| MerckJanuvia | $109 | $64,44488 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $971 | $57,87278 claims |
| AmgenOtezla | $37 | $53,13811 claims |
| PfizerEliquis | $177 | $48,51971 claims |
| Johnson & JohnsonXarelto | $46 | $27,95447 claims |
| Astellas Pharma US IncMyrbetriq | $97 | $19,93235 claims |
| AbbVieLinzess, Savella | $26 | $16,78029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Crane
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.